title: Advances in the treatment of dyslipidemia.
abstract: Although current guidelines do not set specific targets for lowering levels of low-density lipoprotein cholesterol (LDL-C), several lines of evidence support the concept that "lower is better." Statin drugs in combination with new agents now make it possible to lower LDL-C to new lows. Determining the risk of cardiovascular disease in apparently healthy adults and how far to extend treatment for primary prevention has critical implications for public health.
authors.affiliation: Chairman, TIMI Study Group.|Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. E-mail: msabatine@partners.org.|Professor of Medicine, Harvard Medical School, Boston, MA, USA.
authors.forename: Marc S
authors.initials: MS
authors.lastname: Sabatine
mesh_terms: D050197:Atherosclerosis / Q000209:etiology / Q000517:prevention & control*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D011322:Primary Prevention / Q000379:methods*; D012307:Risk Factors
chemical_list: D000960:Hypolipidemic Agents